---
document_datetime: 2026-01-21 14:21:14
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/opdivo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: opdivo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.9832821
conversion_datetime: 2026-01-22 21:22:09.641118
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## OPDIVO

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 15/12/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000317232                     | variations. B.I.c.2 Change in the specification parameters and/or limits of the immediate packaging of the active substance - B.I.c.2.a Tightening of specification limits - Accepted B.II.c.2 Change in test procedure for an excipient - B.II.c.2.a Minor changes to an approved test procedure - Refused                                                                                                                                                                                                                                                                           |            |                   |                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000288087 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.1 and 4.2 of the SmPC following procedure EMEA/H/C/003985/X/0144. In addition, the MAH took the opportunity to update sections 4.4, 4.8, and 5.1 of the SmPC to align it with the new indications and to implement editorial changes to the PI. The Package Leaflet is updated in accordance. The RMP version 46.0 has also been submitted. | 27/11/2025 | SmPC and PL       | Within SmPC section 4.1, the order of indications under each tumour type has been re-organised (where necessary) to reflect the order of the treatment settings. In section 4.2, the majority of the text describing how each regimen is dosed was replaced with tables where all relevant information is included. For more information, please refer to the Summary of Product Characteristics. |
| Variation type II / EMA/VR/0000278256 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation                                                                                                                                                                                                                                                                                                                                                                                                                    | 27/11/2025 | SmPC and Annex II | SmPC new text The results of the final OS analysis, from a phase 3 study (CA209577) evaluating the safety and efficacy of nivolumab monotherapy for the adjuvant treatment of oesophageal or gastro                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                                       | of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment by the competent authority is required* - Accepted Submission of the final report for the final Overall Survival analysis from the post authorisation efficacy study (PAES) CA209577 listed as an obligation in the Annex II of the Product Information. This is a randomized, multicenter, double-blind phase 3 study of adjuvant nivolumab in subjects with resected oesophageal cancer or gastroesophageal cancer who have received chemoradiotherapy followed by surgery. The Annex II and the RMP (version   |            |                 | oesophageal junction cancer, with a minimum follow up of 60 months have been included in section 5.1 of the SmPC. The HR for OS was 0.85 (95.87% CI: 0.70, 1.04), p value = 0.1064. Median OS was 51.71 (95% CI: 41.03, 61.63) months in the nivolumab arm compared with 35.25 (95% CI: 30.72, 48.76) months in the placebo arm. The corresponding Kaplan Meier curves have also been included in the section 5.1 of the SmPC. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000285155 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted                                                                                                                                                                                                                                                               | 13/11/2025 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                                       | study CA2098Y8, listed in the Product Information (PI) Annex II and in the RMP from 28.02.2026 to 28.02.2027.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000279319 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.1 of the SmPC in order to add the final OS data based on final results from study CA209816. This is a randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC. The RMP version 47.0 has also been submitted. In addition, the MAH took | 09/10/2025 |     | SmPC and Annex II | At the final OS analysis with a minimum follow up of 59.9 months, the HR for OS was 0.72 (95.18% CI: 0.52, 1.00), with a statistically significant p value of 0.0479 (stratified log-rank test) for nivolumab in combination with chemotherapy vs. chemotherapy. The HR for OS in patients with tumour PD-L1 expression â‰¥ 1% and stage II -IIIA disease was 0.59 (95% CI: 0.35, 0.98) for nivolumab in combination with chemotherapy vs. chemotherapy. For more information, please refer to the Summary of Product Characteristics. |
| Variation type IB / EMA/VR/0000286391 | B.II.b.2 Change to importer, batch release arrangements and quality control testing of the finished product - B.II.b.2.a Replacement or addition of a site where batch control/testing takes place - Accepted                                                                                                                                                                                                                                                                                                                                                                                        | 24/07/2025 | N/A |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Variation type II / EMA/VR/0000247251 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 10/04/2025 | N/A |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermediate used in the manufacture of a biological/immunological product - Accepted   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|